• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

维拉帕米和环孢素A在不存在膜P-糖蛋白且细胞质游离钙离子浓度无明显变化的情况下，使人类肾肿瘤细胞对长春新碱敏感。

Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.

作者信息

Nygren P, Larsson R

机构信息

Department of Oncology, Uppsala University, Sweden.

出版信息

Biosci Rep. 1990 Apr;10(2):231-7. doi: 10.1007/BF01116583.

DOI:10.1007/BF01116583
PMID:1972632
Abstract

Vincristine (Vcr) dose dependently inhibited growth of the kidney adenocarcinoma cell line ACHN during 4 days of culture. Verapamil (Ver) at 10 microM and cyclosporin A (CsA) at 1 microgram/ml had no effect on cell growth but significantly potentiated the action of Vcr, despite the absence of the multidrug resistance associated membrane P-glycoprotein (P-gp). Neither Ver nor CsA had any acute or long term effects on cytoplasmic free Ca2+ concentration (Ca2+i), except for a small Ver induced increase after 36 h of incubation. The results indicate that Ver and CsA may have a sensitizing effect on chemotherapeutic drug sensitivity also in absence of P-gp. However, these effects are probably not mediated by changes in Ca2+i.

摘要

在4天的培养过程中，长春新碱（Vcr）对肾腺癌细胞系ACHN的生长具有剂量依赖性抑制作用。10微摩尔的维拉帕米（Ver）和1微克/毫升的环孢素A（CsA）对细胞生长无影响，但能显著增强Vcr的作用，尽管不存在与多药耐药相关的膜P-糖蛋白（P-gp）。Ver和CsA对细胞质游离钙浓度（Ca2+i）均无急性或长期影响，仅在孵育36小时后，Ver引起了小幅升高。结果表明，在不存在P-gp的情况下，Ver和CsA对化疗药物敏感性可能具有致敏作用。然而，这些作用可能并非由Ca2+i的变化介导。

相似文献

1
Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.维拉帕米和环孢素A在不存在膜P-糖蛋白且细胞质游离钙离子浓度无明显变化的情况下，使人类肾肿瘤细胞对长春新碱敏感。
Biosci Rep. 1990 Apr;10(2):231-7. doi: 10.1007/BF01116583.
2
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.人类肿瘤细胞与正常细胞对化疗药物及耐药调节剂的体外敏感性差异
Int J Cancer. 1991 Jun 19;48(4):598-604. doi: 10.1002/ijc.2910480419.
3
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.
Cancer Lett. 1990 Nov 5;54(3):125-31. doi: 10.1016/0304-3835(90)90033-t.
4
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.阿霉素筛选出的多药耐药小细胞肺癌细胞系，其特征为细胞质钙离子浓度升高，且在无P-糖蛋白过表达的情况下可被维拉帕米调节耐药性。
Br J Cancer. 1991 Dec;64(6):1011-8. doi: 10.1038/bjc.1991.456.
5
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.人U-937淋巴瘤细胞系中长春新碱耐药性的产生以及对环孢素A和维拉帕米敏感性的增加，且不存在170-kDa P-糖蛋白的过表达。
Int J Cancer. 1994 Jul 15;58(2):269-74. doi: 10.1002/ijc.2910580221.
6
Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).维拉帕米和环孢素A对表达不同水平P-糖蛋白和CP22（亲环蛋白A）的小鼠肿瘤细胞的化学增敏作用
Br J Cancer. 1990 Jul;62(1):89-95. doi: 10.1038/bjc.1990.235.
7
[Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].[增强抗癌药物对肾细胞癌的细胞毒性作用]
Nihon Hinyokika Gakkai Zasshi. 1996 Aug;87(8):1041-7. doi: 10.5980/jpnjurol1989.87.1041.
8
Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells.环孢素A与维拉帕米在克服多药耐药培养人白血病细胞长春新碱耐药性中的协同作用。
Jpn J Cancer Res. 1990 Aug;81(8):834-41. doi: 10.1111/j.1349-7006.1990.tb02653.x.
9
Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells.环孢菌素与多药耐药细胞中P-糖蛋白长春花生物碱结合位点的竞争性相互作用。
J Biol Chem. 1990 Sep 25;265(27):16509-13.
10
Reversal of multidrug resistance by an immunosuppressive agent FK-506.
Cancer Chemother Pharmacol. 1992;29(3):195-200. doi: 10.1007/BF00686252.

引用本文的文献

1
Multidrug resistance increment in a human colon carcinoma cell line by colchicine.
J Physiol Biochem. 2000 Mar;56(1):33-8. doi: 10.1007/BF03179774.
2
Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.美法仑与L-脯氨酰-m-L-肌氨酸-L-对氟苯丙氨酸在人肿瘤细胞系及患者肿瘤细胞原代培养物中的细胞毒性活性比较。
Br J Cancer. 1998 Aug;78(3):328-35. doi: 10.1038/bjc.1998.494.
3
Correlation of expression levels of P-glycoprotein with resistance to adriamycin in a renal adenocarcinoma cell line.肾腺癌细胞系中P-糖蛋白表达水平与阿霉素耐药性的相关性
Urol Res. 1997;25(6):407-12. doi: 10.1007/BF01268857.
4
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.拓扑替康对人肿瘤细胞系及患者来源的人肿瘤细胞原代培养物的细胞毒活性。
Br J Cancer. 1997;76(2):211-9. doi: 10.1038/bjc.1997.364.
5
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.使用代表特定耐药类型的人类细胞系面板对抗癌药物进行表征。
Br J Cancer. 1996 Sep;74(6):888-96. doi: 10.1038/bjc.1996.453.
6
Detection of low-level expression of P-glycoprotein in ACHN renal adenocarcinoma cells.ACHN肾腺癌细胞中P-糖蛋白低水平表达的检测。
Jpn J Cancer Res. 1996 May;87(5):475-9. doi: 10.1111/j.1349-7006.1996.tb00248.x.
7
Characterisation of a vindesine-resistant human small-cell lung cancer cell line.长春地辛耐药人小细胞肺癌细胞系的鉴定
Br J Cancer. 1993 Jul;68(1):74-9. doi: 10.1038/bjc.1993.289.
8
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.阿霉素筛选出的多药耐药小细胞肺癌细胞系，其特征为细胞质钙离子浓度升高，且在无P-糖蛋白过表达的情况下可被维拉帕米调节耐药性。
Br J Cancer. 1991 Dec;64(6):1011-8. doi: 10.1038/bjc.1991.456.